On this page
Prostate cancer (polygenic risk)
Also known as Prostate cancer
Most prostate cancer is not caused by a single faulty gene. Instead, a man's inherited risk usually reflects hundreds of common DNA variants scattered across the genome, each with a tiny individual effect. Added together, these variants form a continuous spectrum of risk. A polygenic risk score sums this inherited contribution to estimate how a man's likelihood compares with other men of similar age and ancestry.
Available at Jeen Health
Clinical tests that include this
Overview
Prostate cancer develops in the prostate, a small gland beneath the bladder that helps produce semen. It is the most common cancer in men in the UK, with around 64,000 new cases diagnosed each year, accounting for more than 30% of all new cancers in men. Lifetime risk is approximately 1 in 8 for White men overall, although this varies markedly by ancestry: it is around 1 in 4 for Black men and closer to 1 in 13 for Asian men. Age is the strongest risk factor, with most cases diagnosed after 65. Many prostate cancers grow slowly and may never cause harm, while a minority are aggressive. Family history and ancestry both raise risk, reflecting a substantial inherited component. For most men this inherited risk is polygenic, built from many common variants rather than one high-risk gene fault, which is what a polygenic risk score aims to capture.
Symptoms & clinical features
Early prostate cancer often causes no symptoms at all, which is why many cases are found through PSA testing or incidentally rather than because a man feels unwell. When symptoms do occur they may include needing to pass urine more often, especially at night, difficulty starting or a weak flow, a feeling of incomplete emptying, or blood in the urine or semen. These features overlap heavily with benign prostate enlargement, which is common with age and is not cancer. Advanced disease can cause bone pain, unexplained weight loss or fatigue. Importantly, having a high polygenic risk score does not change how prostate cancer presents or how it is treated; it only reflects an estimated likelihood of developing the disease, not its symptoms or behaviour.
Video: Is cancer in your genes?
Affected organs
Prostate cancer affects the prostate, a walnut-sized gland in the male reproductive system that sits below the bladder and surrounds the upper part of the urethra. Because of this position it can affect urinary function. If the disease spreads, it most commonly involves nearby lymph nodes and the bones, and less often other organs. The prostate is male-specific, which is why this condition is confined to men.
Risks & severity
A polygenic risk score is usually expressed as a percentile, showing where a man sits relative to others, or as a relative risk compared with the population average. For example, men in the top few per cent of the distribution can have a several-fold higher likelihood of developing prostate cancer than men in the middle. Crucially, the score estimates the chance of developing prostate cancer over time, not how aggressive any cancer would be. Predictive performance varies between conditions and, importantly, by ancestry: most large prostate cancer scores were developed mainly in men of European ancestry, so accuracy can be lower in other groups. A high score raises estimated risk but does not guarantee disease, and a low score does not remove it.
Genetic causes
Prostate cancer is one of the most polygenic of all cancers. Genome-wide association studies have identified hundreds of common variants associated with risk, with the chromosome 8q24 region being among the earliest and most strongly implicated, harbouring several independent risk signals. Other well-replicated loci include those near MSMB, KLK3 (which encodes PSA), TET2, MYC and many additional regions. A widely used multi-ancestry polygenic risk score, for example, combines 269 such variants identified across more than 100,000 cases. Each variant individually shifts risk only slightly; their combined effect is what gives the score its predictive value. Separately, rarer moderate- to high-penetrance variants in genes such as HOXB13 (the G84E variant), BRCA2, ATM and CHEK2 raise risk substantially, but these account for only a minority of cases. Polygenic scoring focuses on the common-variant background that influences risk in the wider population.
Inheritance pattern
Polygenic prostate cancer risk is not inherited in a simple Mendelian way. There is no single gene passed down that determines whether a man will develop the disease. Instead, the many common variants involved are inherited independently from both parents, and each person ends up with a unique combination. Because these variants are common and additive, risk falls along a continuous bell-shaped distribution across the population rather than splitting people neatly into affected and unaffected groups. A man may inherit more or fewer risk-raising variants than his father or brothers, which is why polygenic risk can differ between close relatives. A strong family history often reflects a shared burden of these common variants, sometimes alongside rarer higher-risk faults.
Diagnosis & testing
A polygenic risk score is a risk estimate, not a diagnosis. It is calculated from a DNA sample, typically saliva or blood, by genotyping the relevant common variants and summing their effects using validated weights, then comparing the total against a reference population to produce a percentile or relative risk. It tells a man how his inherited risk compares with other men, but it cannot confirm or exclude cancer, and a high score does not mean cancer is present. Diagnosing prostate cancer itself requires clinical assessment, which may include a PSA blood test, an MRI scan and a prostate biopsy if indicated. A polygenic score is best used as one input alongside age, family history, ancestry and PSA results to inform decisions about monitoring.
Management & lifestyle
There is no way to prevent prostate cancer with certainty, but men identified as being at higher polygenic risk can focus on earlier and more attentive detection. The most relevant step in the UK is an informed discussion with a GP about PSA testing, weighing its benefits against the risk of detecting slow-growing cancers that may never cause harm. Men at elevated risk may reasonably choose to start these conversations earlier and to test more regularly, and any abnormal result can be followed up with MRI and, if needed, biopsy. General lifestyle measures that support overall health, such as maintaining a healthy weight, regular physical activity and not smoking, are sensible although their specific effect on prostate cancer is modest. Awareness of urinary symptoms and prompt reporting also matter. A polygenic score complements, rather than replaces, established NHS assessment and clinical judgement.
UK care pathway
The NHS does not run a national screening programme for prostate cancer, because the PSA test is not reliable enough to be offered to all men. Instead, the Prostate Cancer Risk Management Programme supports informed choice: asymptomatic men aged 50 and over can request a free PSA test after discussing the pros and cons with their GP. Men with symptoms are assessed and, where appropriate, referred for investigation under NICE guidance, which may include MRI and biopsy. A polygenic risk score can help inform these conversations but does not change the underlying NHS pathway.
Frequently asked questions
How is polygenic prostate cancer risk different from a single faulty gene?
A single-gene fault, such as a HOXB13 or BRCA2 variant, is one rare change that on its own substantially raises risk and follows a clear inheritance pattern. Polygenic risk is the opposite: it is the combined effect of hundreds of common variants, each with a tiny individual influence. Most men's inherited risk is polygenic, spread across many variants rather than concentrated in one high-risk gene, which is why a polygenic score gives a graded estimate rather than a yes-or-no answer.
Is a prostate cancer polygenic risk score available on the NHS?
Not routinely. The NHS does not offer polygenic risk scoring for prostate cancer as part of standard care, and there is no national prostate cancer screening programme. The NHS does provide PSA testing through the Prostate Cancer Risk Management Programme for informed men aged 50 and over, and single-gene genetic testing through clinical genetics for those with a strong family history. A polygenic score is currently available privately and is best used to inform discussions with your GP rather than to replace NHS assessment.
Does a high polygenic risk score mean I will get prostate cancer?
No. A high score means your estimated likelihood is greater than average for men of similar age and ancestry, but it is a probability, not a diagnosis or a certainty. Many men with high scores never develop prostate cancer, and some men with low scores do. The score also says nothing about whether any cancer would be slow-growing or aggressive. It is most useful as one factor, alongside age, family history and PSA results, when deciding how closely to monitor.
Does the score work equally well for men of all backgrounds?
Not yet. Most large prostate cancer polygenic scores were developed mainly using data from men of European ancestry, so their accuracy can be lower in men of African, Asian and other ancestries. This matters particularly because Black men have a substantially higher lifetime risk of prostate cancer. Research is actively improving multi-ancestry scores, but until that work matures, results in non-European groups should be interpreted with extra caution and always alongside clinical assessment.
References
- Holt JD, Gerayli F. Prostate Cancer Screening. Primary care. 2019. PMID: 31030827
- Catalona WJ. Prostate Cancer Screening. The Medical clinics of North America. 2018. PMID: 29406053
- Barnes DR, Silvestri V, Leslie G. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute. 2022. PMID: 34320204
- Dunn MW. Prostate Cancer Screening. Seminars in oncology nursing. 2017. PMID: 28343840
- Klein RJ, Vertosick E, Sjoberg D. Prostate cancer polygenic risk score and prediction of lethal prostate cancer. NPJ precision oncology. 2022. PMID: 35396534
- Black MH, Li S, LaDuca H. Validation of a prostate cancer polygenic risk score. The Prostate. 2020. PMID: 33258481
- Parker C, Castro E, Fizazi K. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2020. PMID: 32593798
- Voelker R. What Is Prostate Cancer? JAMA. 2025. PMID: 40705361